Krantz SB: Pathogenesis and treatment of the anemia of chronic disease. Am J Med Sci 1994, 307: 353-359.
Article
CAS
PubMed
Google Scholar
Cavill I: Iron and erythropoietin in renal disease. Nephrol Dial Transplant 2002, 17: 19-23. 10.1093/ndt/17.suppl_5.19
Article
CAS
PubMed
Google Scholar
Rodriguez RM, Corwin HL, Gettinger A, Corwin MJ, Gubler D, Pearl RG: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001, 16: 36-41. 10.1053/jcrc.2001.21795
Article
CAS
PubMed
Google Scholar
Andrews NC: Disorders of iron metabolism. N Engl J Med 1999, 341: 1986-1995. 10.1056/NEJM199912233412607
Article
CAS
PubMed
Google Scholar
Patteril MV, Davey-Quinn AP, Gedney JA, Murdoch SD, Bellamy MC: Functional iron deficiency, infection and systemic inflammatory response syndrome in critical illness. Anaesth Intensive Care 2001, 29: 473-478.
CAS
PubMed
Google Scholar
Viljoen M, Coetzee IH, Roux LJ, Pretorius JP: Anemia in surgical intensive care patients. Haematologica 1994, 79: 19-24.
CAS
PubMed
Google Scholar
Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG: High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998, 44: 361-367.
Article
CAS
PubMed
Google Scholar
Cavill I: Erythropoiesis and iron. Best Pract Res Clin Haematol 2002, 15: 399-409. 10.1016/S1521-6926(02)90004-6
Article
CAS
PubMed
Google Scholar
Kaltwasser JP, Kessler U, Gottschalk R, Stucki G, Moller B: Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001, 28: 2430-2436.
CAS
PubMed
Google Scholar
van Iperen CE, Gaillard CAM, Kraaijenhagen RJ, Braam BG, Marx JJM, van de Wiel A: Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 2000, 28: 2773-2778. 10.1097/00003246-200008000-00015
Article
CAS
PubMed
Google Scholar
Hoen B: Iron and infection: clinical experience. Am J Kidney Dis 1999, Suppl 2: S30-S34.
Article
Google Scholar
Jurado RL: Iron, infections, and anemia of inflammation. Clin Infect Dis 1997, 25: 888-895.
Article
CAS
PubMed
Google Scholar
Besarab A, Frinak S, Yee J: An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999, 10: 2029-2043.
CAS
PubMed
Google Scholar
Collins A, J Ebben, J Ma: Frequent IV iron dosing is associated with higher infectious deaths [abstract]. J Am Soc Nephrol 1997, 8: 190A.
Google Scholar
Cunningham-Rundles S, Giardina PJ, Grady RW, Califano C, McKenzie P, de Sousa M: Effect of transfusional iron overload on immune response. J Infect Dis 2000, Suppl 1: S115-S121. 10.1086/315919
Article
Google Scholar
Hunter RL, Bennett B, Towns M, Vogler WR: Transferrin in disease II: defects in the regulation of transferrin saturation with iron contribute to susceptibility to infection. Am J Clin Pathol 1984, 81: 748-753.
CAS
PubMed
Google Scholar
Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C: Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993, 64: 95-100.
Article
CAS
PubMed
Google Scholar
Hoen B, Kessler M, Hestin D, Mayeux D: Risk factors for bacterial infections in chronic haemodialysis adult patients: a multi-centre prospective survey. Nephrol Dial Transplant 1995, 10: 377-381.
CAS
PubMed
Google Scholar
Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998, 9: 869-876.
CAS
PubMed
Google Scholar
Fishbane S: Review of issues relating to iron and infection. Am J Kidney Dis 1999, Suppl 2: S47-S52.
Article
Google Scholar
Besarab A, Kaiser JW, Frinak S: A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis 1999, 34: 21-28.
Article
CAS
PubMed
Google Scholar
Hudson JQ, Comstock TJ: Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 2001, 23: 1637-1671. 10.1016/S0149-2918(01)80135-1
Article
CAS
PubMed
Google Scholar
Rutherford CJ, Schneider TJ, Dempsey H, Kirn DH, Brugnara C, Goldberg MA: Efficacy of different dosing regimens for recombinant human erythropoietin in a simulated perisurgical setting: the importance of iron availability in optimizing response. Am J Med 1994, 96: 139-145.
Article
CAS
PubMed
Google Scholar
Aggarwal HK, Nand N, Singh S, Singh M, Hemant , Kaushik G: Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India 2003, 51: 170-174.
CAS
PubMed
Google Scholar
Saltissi D, Sauvage D, Westhuyzen J: Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Clin Nephrol 1998, 49: 45-48.
CAS
PubMed
Google Scholar
Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC: Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002, 186: 518-522. 10.1067/mob.2002.121894
Article
CAS
PubMed
Google Scholar
Bader D, Kugelman A, Maor-Rogin N, Weinger-Abend M, Hershkowitz S, Tamir A, Lanir A, Attias D, Barak M: The role of high-dose oral iron supplementation during erythropoietin therapy for anemia of prematurity. J Perinatol 2001, 21: 215-220. 10.1038/sj.jp.7200522
Article
CAS
PubMed
Google Scholar
Franz AR, Mihatsch WA, Sander S, Kron M, Pohlandt F: Prospective randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams. Pediatrics 2000, 106: 700-706.
Article
CAS
PubMed
Google Scholar
Tarng D-C, Huang T-P, Tzen W, Yang W-C: Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int Suppl 1999, 69: S107-S118. 10.1046/j.1523-1755.1999.055Suppl.69107.x
Article
CAS
PubMed
Google Scholar
Rohling RG, Zimmermann AP, Breymann C: Intravenous versus oral iron supplementation for preoperative stimulation of hemoglobin synthesis using recombinant human erythropoietin. J Hematother Stem Cell Res 2000, 9: 497-500. 10.1089/152581600419161
Article
CAS
PubMed
Google Scholar
Fishbane S: Safety in iron management. Am J Kidney Dis 2003,41(5 suppl):18-26. 10.1016/S0272-6386(03)00373-1
Article
PubMed
Google Scholar
Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002, 40: 90-103. 10.1053/ajkd.2002.33917
Article
CAS
PubMed
Google Scholar
Beris P: The use of iron to increase red cell mass. Can J Anaesth 2003, Suppl: S3-S9.
Google Scholar
Burns DL, Mascioli EA, Bistrian BR: Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia. Nutrition 1996, 12: 411-415. 10.1016/S0899-9007(96)00095-0
Article
CAS
PubMed
Google Scholar
Kumpf VJ: Parenteral iron supplementation. Nutr Clin Pract 1996, 11: 139-146.
Article
CAS
PubMed
Google Scholar
Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ: Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999, 27: 2346-2350. 10.1097/00003246-199911000-00004
Article
CAS
PubMed
Google Scholar
Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, Corwin MJ, Colton T: Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002, 288: 2827-2835. 10.1001/jama.288.22.2827
Article
CAS
PubMed
Google Scholar
Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000, 11: 530-538.
CAS
PubMed
Google Scholar
Silverberg DS, Blum M, Agbaria Z, Deutsch V, Irony M, Schwartz D, Baruch R, Yachnin T, Steinbruch S, Iaina A: The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period. Clin Nephrol 2001, 55: 212-219.
CAS
PubMed
Google Scholar
Olijhoek G, Megens JG, Musto P, Nogarin L, Gassmann-Mayer C, Vercammen E, Hayes-Licitra SA: Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Transfusion 2001, 41: 957-963. 10.1046/j.1537-2995.2001.41070957.x
Article
CAS
PubMed
Google Scholar
Gwardschaladse C: Exogenous iron supplementation is not necessary in critically ill patients receiving recombinant epoietin alpha [abstract]. Crit Care Med 2002, 30: A63.
Article
Google Scholar
Horl WH: Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant 2002, Suppl 11: 35-38.
Article
Google Scholar
Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 1999, 55: 2477-2486. 10.1046/j.1523-1755.1999.00479.x
Article
CAS
PubMed
Google Scholar
Britton RS, Leicester KL, Bacon BR: Iron toxicity and chelation therapy. Int J Hematol 2002, 76: 219-228.
Article
CAS
PubMed
Google Scholar
Meneghini R: Iron homeostasis, oxidative stress, and DNA damage. Free Rad Biol Med 1997, 23: 783-792. 10.1016/S0891-5849(97)00016-6
Article
CAS
PubMed
Google Scholar
Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD: Diabetic nephropathy in hypertransfused patients with thalassemia. Diabetic Care 1998, 21: 1306-1309.
Article
CAS
Google Scholar
Saran M, Michel C, Stettmaier K, Bors W: Arguments against the significance of the Fenton reaction contributing to signal pathways under in vivo conditions. Free Rad Res 2000, 33: 567-579.
Article
CAS
Google Scholar
Urbanski NK, Beresewicz A: Generation of OH initiated by interaction of Fe and Cu with dioxygen; comparison with the Fenton chemistry. Acta Biochim Pol 2000, 47: 951-962.
CAS
PubMed
Google Scholar
Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL: Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990, 322: 1689-1692.
Article
CAS
PubMed
Google Scholar
Punnonen K, Irjala K, Rajamaki A: Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997, 89: 1052-1057.
CAS
PubMed
Google Scholar
Hamstra RD, Block MH, Schocket AL: Intravenous iron dextran in clinical medicine. JAMA 1980, 243: 1726-1731. 10.1001/jama.243.17.1726
Article
CAS
PubMed
Google Scholar
Jain AK, Bastani B: Safety profile of a high dose ferric gluconate in patients with severe chronic renal insufficiency. J Nephrol 2002, 15: 681-683.
CAS
PubMed
Google Scholar
Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM: A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001, 16: 1239-1244. 10.1093/ndt/16.6.1239
Article
CAS
PubMed
Google Scholar
Yee J, Besarab A: Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis 2002, 40: 1111-1121. 10.1053/ajkd.2002.36853
Article
CAS
PubMed
Google Scholar